TY - JOUR
T1 - Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery
AU - Meyer, Larissa A.
AU - Shi, Qiuling
AU - Lasala, Javier
AU - Iniesta, Maria D.
AU - Lin, Huei Kai
AU - Nick, Alpa M.
AU - Williams, Loretta
AU - Sun, Charlotte
AU - Wang, Xin Shelley
AU - Lu, Karen H.
AU - Ramirez, Pedro T.
N1 - Funding Information:
This work was supported by the National Cancer Institute/National Institutes of Health through a K07-CA20103 (Meyer) and R01 CA205146 (Wang and Shi). This work was also supported by the Cancer Center Support Grant, P30CA016672. Meyer and Sun reported research support for unrelated research from AstraZeneca. Meyer reported participation in an advisory board for Clovis Oncology.
Funding Information:
This work was supported by the National Cancer Institute through a K07 CA20103 (Meyer) and National Cancer Institute R01 CA205146 (Wang and Shi). This work was also supported by the National Cancer Institute , P30 CA016672 .
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2019/3
Y1 - 2019/3
N2 - Objective: To compare symptom burden and functional recovery in women undergoing primary cytoreductive surgery (PCS) or neoadjuvant chemotherapy (NACT) and interval cytoreductive surgery (ICS) within an enhanced recovery after surgery program (ERAS). Methods: Symptom burden was measured using the MD Anderson Symptom Inventory-Ovarian Cancer, a 27-item validated tool that was administered preoperatively, daily while hospitalized, and weekly for 8 weeks after hospital discharge. Mixed-effect modeling was performed. Results: 196 patients (71 PCS, 125 ICS) participated. Patients in the PCS group were younger, median age of 59 vs. 63 in ICS group. Median length of stay was 4 days for PCS and 3 days for ICS group. PCS pts had a significantly higher median surgical complexity score (4 vs. 2, p = 0.002), and longer median surgical time (257 min vs. 220 min, p = 0.03). While patients undergoing PCS had significantly different symptom burden profiles prior to surgery compared to those undergoing ICS, there were no significant differences in symptoms in the immediate in-hospital and extended post-hospital discharge period. Irrespective of the timing of surgery in relation to chemotherapy, patients undergoing intermediate or high complexity surgery had more nausea, fatigue, and higher total interference scores compared to patients undergoing low complexity surgery. Conclusion: Within a center with a standardized, systematic method for patient selection for PCS and a standardized ERAS care pathway, there were not significant differences in surgery-related symptoms related to recovery between patients undergoing PCS or ICS. However, patient-reported symptom burden and symptom interference did meaningfully differentiate based on surgical complexity score.
AB - Objective: To compare symptom burden and functional recovery in women undergoing primary cytoreductive surgery (PCS) or neoadjuvant chemotherapy (NACT) and interval cytoreductive surgery (ICS) within an enhanced recovery after surgery program (ERAS). Methods: Symptom burden was measured using the MD Anderson Symptom Inventory-Ovarian Cancer, a 27-item validated tool that was administered preoperatively, daily while hospitalized, and weekly for 8 weeks after hospital discharge. Mixed-effect modeling was performed. Results: 196 patients (71 PCS, 125 ICS) participated. Patients in the PCS group were younger, median age of 59 vs. 63 in ICS group. Median length of stay was 4 days for PCS and 3 days for ICS group. PCS pts had a significantly higher median surgical complexity score (4 vs. 2, p = 0.002), and longer median surgical time (257 min vs. 220 min, p = 0.03). While patients undergoing PCS had significantly different symptom burden profiles prior to surgery compared to those undergoing ICS, there were no significant differences in symptoms in the immediate in-hospital and extended post-hospital discharge period. Irrespective of the timing of surgery in relation to chemotherapy, patients undergoing intermediate or high complexity surgery had more nausea, fatigue, and higher total interference scores compared to patients undergoing low complexity surgery. Conclusion: Within a center with a standardized, systematic method for patient selection for PCS and a standardized ERAS care pathway, there were not significant differences in surgery-related symptoms related to recovery between patients undergoing PCS or ICS. However, patient-reported symptom burden and symptom interference did meaningfully differentiate based on surgical complexity score.
KW - Cytoreductive surgery
KW - Enhanced recovery after surgery
KW - Neoadjuvant chemotherapy
KW - Ovarian Cancer
KW - Patient reported outcomes
KW - Surgical complexity
UR - http://www.scopus.com/inward/record.url?scp=85056482290&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056482290&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2018.10.044
DO - 10.1016/j.ygyno.2018.10.044
M3 - Article
C2 - 30876495
AN - SCOPUS:85056482290
SN - 0090-8258
VL - 152
SP - 501
EP - 508
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 3
ER -